Browsing by Author "Serrano, F. G."

Now showing 1 - 3 of 3
  • Thumbnail Image
    Item
    Andrographolide reduces cognitive impairment in young and mature AβPPswe/PS-1 mice
    (2014) Serrano, F. G.; Tapia-Rojas, Cheril; Carvajal, F. J.; Hancke, J.; Cerpa Nebott, Waldo Francisco; Inestrosa Cantín, Nibaldo
  • Thumbnail Image
    Item
    Steroid Hormones and Their Action in Women's Brains: the Importance of Hormonal Balance
    (2018) Del Río, J. P.; Alliende, M. I.; Molina, N.; Serrano, F. G.; Molina, S.; Vigil Portales, María del Pilar; Del Río, J. P.; Alliende, M. I.; Molina, N.; Serrano, F. G.; Molina, S.; Vigil Portales, María del Pilar; Del Río, J. P.; Alliende, M. I.; Molina, N.; Serrano, F. G.; Molina, S.; Vigil Portales, María del Pilar; Del Río, J. P.; Alliende, M. I.; Molina, N.; Serrano, F. G.; Molina, S.; Vigil Portales, María del Pilar
  • No Thumbnail Available
    Item
    Tetrahydrohyperforin prevents cognitive deficit, Aβ deposition, tau phosphorylation and synaptotoxicity in the APPswe/PSEN1ΔE9 model of Alzheimer's disease: a possible effect on APP processing
    (2011) Inestrosa, N. C.; Tapia-Rojas, C.; Griffith, T. N.; Carvajal, F. J.; Benito, M. J.; Rivera-Dictter, A.; Alvarez, A. R.; Serrano, F. G.; Hancke, J. L.; Burgos, P. V.; Parodi, J.; Varela-Nallar, L.
    Alzheimer's disease (AD) is a neurodegenerative disorder characterized by a progressive deterioration of cognitive abilities, amyloid-beta peptide (A beta) accumulation and synaptic alterations. Previous studies indicated that hyperforin, a component of the St John's Wort, prevents A beta neurotoxicity and some behavioral impairments in a rat model of AD. In this study we examined the ability of tetrahydrohyperforin (IDN5607), a stable hyperforin derivative, to prevent the cognitive deficit and synaptic impairment in an in vivo model of AD. In double transgenic APPswe/PSEN1DE9 mice, IDN5706 improves memory and prevents the impairment of synaptic plasticity in a dose-dependent manner, inducing a recovery of long-term potentiation. In agreement with these findings, IDN5706 prevented the decrease in synaptic proteins in hippocampus and cortex. In addition, decreased levels of tau hyperphosphorylation, astrogliosis, and total fibrillar and oligomeric forms of A beta were determined in double transgenic mice treated with IDN5706. In cultured cells, IDN5706 decreased the proteolytic processing of the amyloid precursor protein that leads to A beta peptide generation. These findings indicate that IDN5706 ameliorates AD neuropathology and could be considered of therapeutic relevance in AD treatment.